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ABSTRACT 
Extended release products are designed to release their medication in a controlled manner at a predetermined rate, duration, and location to 
achieve and maintain optimum therapeutic blood levels of a drug. The objective of the study is to formulate and evaluate Ilaprazole Controlled 
release tablets comparable to the innovator product. F1-F9 formulations were prepared using varying concentrations of super disintegrates 
like Crospovidone, Croscarmellose sodium and Sodium starch glycolate in different concentrations. Based on the hardness, friability, weight 
variation, drug content, F6 formulation was found to be optimised. The selected F6 formulation was sub coated with HPMC P 50 and followed 
by enteric coating with Acryl-EZE-80 (Eudragit L100-55). 3 formulations (F10-F12) were prepared by using coating. Among the three 
formulations, F11 formulation was found to be best. FTIR studies were carried out to find out drug and excipient compatibility studies, the 
studies revealed that there were no interactions. DSC studies also carried out to demonstrate any changes in physical forms of the drug 
molecule. 
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1. INTRODUCTION 
Ilaprazole is a substituted benzimidazole which is anti‐
ulcerous compound known for decreasing gastric acid 
secretion. This compound, also known as proton pump 
inhibitor (PPI) is commonly indicated for the treatment of 
gastric ulcer, peptic ulcer, duodenal ulcers, erosive or 
ulcerative GERD (Gastro esophageal reflux disease), 
symptomatic GERD, pathological hypersecretory conditions 
(Zollinger‐Ellison). Ilaprazole is practically insoluble in 
water, more soluble in alkaline medium as compared to 
acidic medium. The stability of Ilaprazole is a function of pH; 
it is rapidly degraded in acid media, and is more stable under 
alkaline conditions. Therefore exposure of Ilaprazole to the 
acidic content of the stomach would lead to significant 
degradation of the drug and hence, reduced bioavailability. 
Extended release dosage forms are the best formulations 
which are used for drugs that are destroyed in the gastric 
fluids, or cause gastric irritation, or are absorbed 
preferentially in the intestine. Such preparations contain an 
alkaline core material comprising the active substance, a 
separating layer and enteric coating layer.1 
Enteric polymer coatings contain ionisable carboxylic groups 
which shall remain insensitive to the acidic state of the 
stomach, nevertheless dissolves or disintegrates readily in 
the alkaline surroundings of the intestine. The different 
release characteristics of the enteric polymers have profound 
impact upon the pharmacokinetic parameters of the drug. An 
Ideal enteric polymer should possess a hydrophilic and 
hydrophobic monomeric unit. Methacrylic acid and methyl 
methacrylate could make an ideal hydrophilic and 
hydrophobic unit respectively.  
The aim of present work was to prepare extended release 
i.e., enteric coated tablets of Ilaprazole by using HPMC-P 50 
and Eudragit L 100 in side vented perforated coating pan to 
prevent degradation in the stomach due to the acidic 
environment or gastric enzymes and to study the factors 
affecting the film coating of tablets performed in a perforated 
pan coater and further optimization of enteric coating 
formula is done which implicate more significant effects on 
dissolution profile of tablet. 
2. MATERIALS AND METHODS 
Materials: Ilaprazole was procured as a gift sample from 
Zydus Cadila Pvt. Ltd., Crospovidone, Sodium starch 
glycolate, Croscarmellose sodium and Sodium carbonate 
was obtained from Yarrow chem products. Mumbai, Avicel-
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PH102, Magnesium stearate, Talc, Lactose was purchased 
from Signet chemicals, Mumbai. 
Preparation of core tablets 
Direct compression method: The core tablets of Ilaprazole 
formulations were prepared by direct compression method. 
All the ingredients were accurately weighed, milled and 
passed through sieve no. 60 (250 microns) to get uniformly 
distributed and uniform sized particles. The ingredients 
were then blended in a cube mixer for 30 minutes. The 
homogeneously blended mixture was then compressed on a 
10 station tablet punching machine using 6 mm round 
biconvex punches at a pressure of 4 to 6 kg/cm2. All the 
formulations were prepared with similar blending time and 
compaction conditions.2-7 The composition of the core tablets 
is shown in Table. 1. 
 
Table 1: Preparation of Ilaprazole Core Tablets 
S.N. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Ilaprazole 10 10 10 10 10 10 10 10 10 
2 Sodium Carbonate 14 14 14 14 14 14 14 14 14 
3 CP 5 10 15 - - - - - - 
4 SSG - - - 5 10 15 - - - 
5 CCS - - - - - - 5 10 15 
6 Avicel-PH102 90 90 90 90 90 90 90 90 90 
7 Talc 2 2 2 2 2 2 2 2 2 
8 Mg.streate 4 4 4 4 4 4 4 4 4 
9 Lactose 75 70 65 75 70 65 75 70 65 
 Total 200 200 200 200 200 200 200 200 200 
*Crospovidone, *Croscarmellose sodium, *Sodium starch glycolate. 
 
3. RESULTS AND DISCUSSION 
Compatibility Studies- FTIR: 
Drug excipient compatibility study was done by IR.  The IR 
spectrum of Ilaprazole and physical mixture of drug and 
excipient were recorded using Bruker. The pellets were 
prepared in KBr press using physical mixture of drug, 
excipient and KBr.  
 
 
Figure 1: FTIR spectra of Ilaprazole pure Drug 
 
Figure 2: FTIR Spectra of Acryl-Eze 
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Figure 3: FTIR spectra of optimized formulation 
 
Differential Scanning Calorimetry (DSC): 
The compatibility and interactions between Ilaprazole and 
adjuvants were checked using differential scanning 
calorimetry (DSC). Any possible drug polymer interaction 
can be studied by thermal analysis. The DSC study was 
performing on pure drug (Ilaprazole) and Optimized 
Formulations. The study was carried out using Hitachi 6300. 
The 2 mg of sample were heated in a hermetically sealed 
aluminum pans in the temperature range of 30-220ºC at 
heating rate of 10ºc /min under nitrogen flow of 40ml/min. 
Finally hence their no interaction was found between drug 
and the Adjuvents. 
 
 
Figure 4: Differential Scanning Calorimetry analysis of Ilaprazole Pure Drug 
 
Figure 5: Differential Scanning Calorimetry analysis of Optimized Formulation 
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Table 2: Physical properties of the powder blends of the batches F1 to F9 8-12 
Parameters  F1  F2  F3  F4  F5  F6 F7 F8 F9 
Angle of repose 26.29±1.3
5  
28.65±1.
09  
26.09±1.
76  
27.54±1.
23  
30.71±1.
13  
27.69±1.
16  
27.55±1.
21  
29.38±1.
08  
26.47±1.
15  
Bulk density 
(gm/cc)  
0.54±0.12  0.53±0.0
6  
0.455±0.
08  
0.43±0.0
5  
0.45±0.0
9  
0.48±0.0
7  
0.52±0.0
2  
0.53±0.0
6  
0.57±0.1
6  
Tapped density 
(gm/cc)  
0.66±0.13  0.65±0.1
2  
0.55±0.1
6  
0.52±0.1
4  
0.53±0.0
9  
0.57±0.0
6  
0.62±0.1
2  
0.64±0.1
8  
0.69±0.1
3  
Carr’s index (%) 12.18  11.46  14.18  10.46  9.09  11.78  14.12  13.18  12.39  
Hausner’s ratio  1.0  1.11  1.09  1.05  1.03 1.10  1.08  1.07  1.05  
 
Table 3: Evaluation of Ilaprazole core tablets F1 to F9 
Formulation Hardness 
(kg/cm2) 
Friability 
(%) 
Weight variation 
(mg) 
Thickness 
(mm) 
Drug Content 
(%) 
F1 4.3±0.45 0.65±0.01 199.35±0.34 3.33±0.8 99.89±0.22 
F2 4.8±0.14 0.78±0.11 198.73±0.43 3.63±0.1 99.35±0.56 
F3 4.2±0.26 0.51±0.26 200.18±0.87 3.83±0.9 98.75±0.34 
F4 4.1±0.32 0.89±0.09 199.56±0.61 3.66±0.3 99.33±0.65 
F5 4.3±0.41 0.54±0.50 200.53±0.68 3.34±0.7 99.14±0.78 
F6 4.9±0.32 0.69±0.12 199.96±0.57 3.26±0.8 99.49±0.44 
F7 4.2±0.41 0.72±0.11 198.46±0.98 3.88±0.1 98.53±0.86 
F8 4.6±0.85 0.51±0.25 200.31±0.17 3.96±0.3 98.16±0.57 
F9 4.7±0.66 0.65±0.12 199.44±0.55 3.55±0.9 99.86±0.98 
 
Table 4: Coating dispersion composition and coating process parameters 
S. N. Parameters 
Sub Coat 
Layer 
Enteric Coat Layer 
F10 F11 F12 
1 Dispersion solid content (%) 12 20 20 20 
2 Powder (gms) HPMC Acryl-EZE-80 Acryl-EZE-80 Acryl-EZE-80 
3 Deionised water - 320 320 320 
4 Iso propyl alcohol 127 - - - 
5 Dichloro methane 225 - - - 
6 Total dispersion  (gms) 400 400 400 400 
7 Mixing time (min) 40 20 20 20 
8 Theoretical wt gain 2 8 12 16 
9 Pan speed (rpm) 12 15 15 15 
10 Inlet temperature(0C) 45 55 55 55 
11 Atomization air pressure (bar) 2 1.5 1.5 1.5 
12 Pan size (Inches) 12 12 12 12 
 
Table 5: Compilation of In-vitro Release of Ilaprazole ER tablets prepared Formulations from F10 to F12 and Marketed 
Product (Adiza) 
S. N. Sample Time 
(minutes) 
Cumulative % drug release 
F10 F11 F12 M 
1 60 9.91±0.65 8.43±1.65 6.52±0.61 8.52±0.55 
2 120 39.3±0.35 38.4±0.29 34.5±0.31 37.5±0.39 
3 180 48.3±0.11 46.3±0.46 41.4±0.81 45.9±0.41 
4 240 55.5±0.42 56.1±0.30 51.6±0.43 56.4±0.27 
5 360 65.1±0.98 66.4±0.29 60.3±0.98 64.8±0.37 
6 480 73.8±0.32 77.5±0.43 69.2±0.23 75.4±0.41 
7 540 80.1±0.33 86.4±0.11 75.3±0.67 85.3±0.29 
8 600 88.5±0.38 89.9±0.36 84.9±0.89 89.1±0.45 
9 720 93.4±0.45 99.6±0.29 95.1±0.53 98.4±0.17 
The data are presented as mean value ± S.D. (N = 3) 
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Figure 6: Dissolution profiles of Formulations F10-F12 and Adiza (M) 
 
4. CONCLUSION 
The conclusions of the present research work are as follows: 
 The objective of the study is to formulate and evaluate 
Ilaprazole Extended Release tablets comparable to the 
innovator product. 
 IR spectra indicated the absence of probable chemical 
interaction between the drug and polymers used in 
three different proportions. 
 F1-F9 formulations (core tablets) were prepared using 
varying concentrations of super disintegrates. 
 Based on the hardness, weight variation, friability, 
drug content, F6 formulation was found to be 
optimized. 
 The selected F6 formulation was coated with the pH 
dependent polymers such as acrylic acid derivatives. 
 3 formulations (F10, F11, and F12) were prepared by 
using enteric coating materials. 
 Among the three formulations, F11 formulation was 
found to be best based on dissolution parameters. 
 Under  the  study  of  kinetic  models, Four models  
have  been  studied  namely  Zero Order,  First  Order,  
Higuchi, Korsmeyer’s-Peppas  model.  It was found that 
the drug release followed Zero order kinetic having 
maximum R2 value is 0.98. 
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